As a little girl, I can remember loving lavender plants because of the pretty purple flower and yummy smell. As I’ve gotten older, my appreciation for the plant has remained, and it’s actually become an integral part of my self-love and wellness practice.
It’s shown to host a handful of benefits, in addition to the highly publicized ones like stress-reduction and sleep promotion—though those are two of my favorite perks! This week, I want to suggest adding the healing plant in one way or another, depending on what your body and mind need.
Challenge: Start using lavender
From oils to the actual plant, here’s what lavender can help and heal:
Lavender essential oil
I’d LOVE to know how you use lavender in your routine if you already do so! And if not, here’s to its benefits and relaxing vibes.
Contributer: Geri Kirsch
UCLA professor Dale Bredesen does a study showing nearly complete resolution of dementia symptoms with a functional medicine approach: Optimize diet, increase and improve sleep, reduce stress, exercise regularly, stimulate brain function, analyze and replete nutrients including antioxidants and mitochondrial function, replace hormones including sex hormones and even T3! in the elderly, remove heavy metals… The full article is long, but definitely check out the summary table link below…
Reversal of cognitive decline: A novel therapeutic program
Aging (Albany NY). 2014 Sep; 6(9): 707–717.
Published online 2014 Sep 27.
Author: Dale E Bredesen
This report describes a novel, comprehensive, and personalized therapeutic program that is based on the underlying pathogenesis of Alzheimer’s disease, and which involves multiple modalities designed to achieve metabolic enhancement for neurodegeneration (MEND). The first 10 patients who have utilized this program include patients with memory loss associated with Alzheimer’s disease (AD), amnestic mild cognitive impairment (aMCI), or subjective cognitive impairment (SCI). Nine of the 10 displayed subjective or objective improvement in cognition beginning within 3-6 months, with the one failure being a patient with very late stage AD. Six of the patients had had to discontinue working or were struggling with their jobs at the time of presentation, and all were able to return to work or continue working with improved performance. Improvements have been sustained, and at this time the longest patient follow-up is two and one-half years from initial treatment, with sustained and marked improvement. These results suggest that a larger, more extensive trial of this therapeutic program is warranted. The results also suggest that, at least early in the course, cognitive decline may be driven in large part by metabolic processes. Furthermore, given the failure of monotherapeutics in AD to date, the results raise the possibility that such a therapeutic system may be useful as a platform on which drugs that would fail as monotherapeutics may succeed as key components of a therapeutic system.
Full article: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221920/